Recon: GSK sees sales growth in 2022; EMA sets up new real-world data center

• Pfizer CEO says chances are ‘very high’ FDA will approve low-dose Covid shots for kids under 5 (CNBC)
• Pfizer’s 2022 outlook falls short of Wall Street’s lofty expectations (FT)
• CVS expects 70%-80% drop in COVID vaccine administration in 2022 (Reuters)
• CVS inks a deal with Medable to enroll more patients in clinical trials (STAT)
• Purdue Pharma bankruptcy mediator says Sacklers, US states closer to deal over opioid claims (Reuters)
• U.S. biotech Sarepta loses bid to challenge rival's muscular dystrophy patents (Reuters)
• ‘I have a right to change my mind’: A top FDA regulator is unapologetic over his about-face on Chinese cancer drugs (STAT)
• FDA’s agenda in limbo as Biden’s nominee stalls in Senate (AP)

• GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off  (Reuters) (FT)
• Chinese healthcare stocks sell off after US adds companies to ‘unverified’ list (FT)
• Qiagen forecasts profit above estimates as non-COVID businesses rebound (Reuters)
• EU ramps up collection of public health data to improve drug reviews (Reuters) (EMA)
• Global COVID response program 'running on fumes' amid budget shortfall (Reuters)
• TGA provisionally approves AstraZeneca's COVID-19 vaccine as booster dose (TGA)

• EU wants pandemic treaty to ban wildlife markets, reward virus detection (Reuters)

• Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy (Fierce)
• Premature birth drug saga drags on as Covis questions fairness of FDA hearing (Endpoints)
• Checkmate plucks BMS exec Bash to be new CEO (Fierce)
• After Q4 sales sink, Amgen CEO Bob Bradway details lofty growth strategy for 2030: Can he pull it off? (Endpoints)
• SMC approves Biogen’s Vumerity for patients with multiple sclerosis (PMLive)
• With first human data, long-struggling Silence Therapeutics leaps into next big cardiovascular race (Endpoints)
• Taking on Big Pharma-sized indications, tiny biotech claims early win in fat loss. Will it translate to diabetes, NASH and beyond? (Endpoints)
• Novo Nordisk's Wegovy passes NICE checkpoint on course to blockbusterland (Fierce)
• How PDUFA VII can catalyze ‘lightspeed’ vaccine and drug development (STAT)

• Federal Investigation Into Spine Surgeries Uses Mob Laws to Target Health Care Fraud (KHN)
• Zimmer gives investors first look at its dental & spine spinoff (MedtechDive)
• BioCardia, Cook Medical land FDA breakthrough nods in latest designations (MedtechDive)
• Element Biosciences acquires Loop Genomics to add long-read tech to DNA sequencing platform (Fierce)
• Potential Risk of Strangulation in Children who Use Enteral Feeding Delivery Sets (FDA)

• FTC Gets More Time To Review Pfizer's $6.7B Arena Deal (Law360)
• New England Compounding Center's National Sales Director Sentenced (FDA)
• The fall of Eric Lander and the end of science’s ‘big ego’ era (STAT)